We have seen for some time now that the Indian pharmaceutical industry is under sharp scrutiny from U.S. regulators. In particular, the U.S. Food and Drug Administration has stepped up its inspection and enforcement levels for those companies. Now comes word that Indian generic drug maker Wockhardt joins the list of Indian firms in trouble. According to Reuters, the latest FDA-483 revealed that Wockhardt’s Shendra plant failed to report negative…
The post Woe Is Me – Compliance Needs to Be Job 1 in India appeared first on Whitelaw Compliance Group, LLC.
